Bloomios, Inc. (BLMS)
| Previous close | 1.0300 |
| Open | 1.0100 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.0100 - 1.0100 |
| 52-week range | 0.5310 - 2.7900 |
| Volume | |
| Avg. volume | 1,224 |
| Market cap | 14.393M |
| Beta (5Y monthly) | -4.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1340 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Bloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer
Bloomios, Inc. (the "Company") (OTCQB: BLMS), a leading white-label and private-label manufacturer and wholesaler of hemp-derived nutraceutical, cosmetics and pet products, has acquired Infusionz, a wholly-owned subsidiary of Upexi (NASDAQ: UPXI).
- PR Newswire
Upexi Announces Sale of Select CBD Assets for $23.5 Million
Upexi Inc. (NASDAQ: UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced the sale of select CBD assets to Bloomios, Inc. (OTC: BLMS) for approximately $23.5 million.
- PR Newswire
Bloomios to Develop and Produce New Range of Private-Label Products Utilizing, Ashwagandha, Melatonin, Kratom, Lion's Mane, Valerian Root, Reishi Mushroom and other Natural Ingredients
Bloomios, Inc. (OTCQB: BLMS), a leading hemp and nutraceutical manufacturer specializing in full service product development, R&D and compliance solutions, has been engaged by several CBD, nootropic and nutraceuticals brands to develop and produce a new range of private-label consumer health and wellness products.
